|Table of Contents|

Relationship between ERCC1,TS and TUBB3 in gastric cancer and sensitivity of chemotherapeutic drugs in vitro

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2018 02
Page:
166-169
Research Field:
Publishing date:

Info

Title:
Relationship between ERCC1,TS and TUBB3 in gastric cancer and sensitivity of chemotherapeutic drugs in vitro
Author(s):
Liu Xinfu1; Yin Chan1; Zhang Hui1; Sun Jianqun1; Liu Tengfei2
1.Department of Oncology,Shaoyang Central Hospital,Hunan Shaoyang 422000,China;2.Department of Pathology,Nanfang Hospital,Southern Medical University,Guangdong Guangzhou 510515,China.
Keywords:
gastric cancer; ERCC1; TS; TUBB3
PACS:
R735.2
DOI:
10.3969/j.issn.1672-4992.2018.02.002
Abstract:
Objective:Analyzing the relationships between expressions of ERCC1,TS and TUBB3 protein with cisplatin,5-fluorouracil and paclitaxel chemotherapy response.Methods:This study reviewed the fresh specimens of 48 patients with gastric cancer after surgical operation.All fresh specimens of gastric cancer were collected and each cancer tissue samples were divided into two parts,a part of samples used for IHC detection ERCC1,TS and TUBB3 expression in there organizations,another part used for the original generation of cultured cells,the cells for drug sensitive test,and then determined by ATP-tumor chemosensitivity assay were used to detect cell proliferation activity of cancer cells resistant index calculation.Results:45 cases of 48 cases of gastric cancer cell to obtain valid data,ERCC1 high expression in 21 cases (46.67%),low expression in 24 cases (53.33%).Combined with susceptibility results obtained before in vitro,there were 7 cases of drug sensitivity in 21 cases of ERCC1 high expression group,17 cases of drug sensitivity in 24 cases (70.83%) of ERCC1 low expression group.ERCC1 high expression group was obviously lower than the low expression group to sensitivity cisplatin,and the differences were significant statistically (P＜0.05).TS high expression in 19 cases (42.22%),low expression in 26 cases (57.78%),there were 5 cases of drug sensitivity in 19 cases of TS high expression group,18 cases of drug sensitivity in 26 cases of TS low expression group.TS high expression group was obviously lower than the low expression group to sensitivity 5-fluorouracil (P＜0.01),TUBB3 high expression in 22 cases (48.89%),low expression in 23 cases (51.11%),there were 5 cases of drug sensitivity in 22 cases of TUBB3 high expression group,16 cases of drug sensitivity in 23 cases of TUBB3 low expression group.TUBB3 high expression group was obviously lower than the low expression group to sensitivity paclitaxel (P＜0.01).Conclusion:The expression of ERCC1,TS and TUBB3 in gastric cancer cell were associated with drug resistance,low expression group were lower than high expression group.ERCC1，TS and TUBB3 could be assessment of the chemotherapy sensitivity and clinical outcome indicators in gastric cancer.

References:

［1］Zhang Wei.Clinical application of bioluminescence tumor chemosensitivity assay in vitro［J］.Oncology Progress Journal,2005,3（5）：427-434.［张伟.生物荧光肿瘤体外药敏检测技术的临床应用及其探讨［J］.癌症进展杂志,2005,3（5）：427-434.］
［2］Squiers MH,Fisher SB,Fisher KE,et al.Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma［J］.Cancer,2013,119(17):3242-3250.
［3］Sevin BU,Peng ZL,Perras JP,et al.Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing［J］.Gynecologic Oncology,1988,31(1):191-204.
［4］Konecny G,Crohns C,Pegtam M,et al.Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer［J］.Gynecologic Oncology,2000,77(2):258-263.
［5］Kawamura H,Ikeda K,Takiyama I,et al.The usefulness of the ATP assay with serum-free culture for chemosensitivity testing of gastrointestinal cancer［J］.European Journal of Cancer (Oxford,England:1990),1997,33(6):960-966.
［6］Qin X,Yao W,Li W,et al.ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy［J］.Tumour Biology,2014,35(5):4697-4704.
［7］Yu WH,Wang YX,Guo JQ,et al.Genetic variability of ERCC1 and ERCC2 influences treatment outcomes in gastric cancer［J］.Genetics and Molecular Research:GMR,2015,14(4):17529-17535.
［8］Gerhard R,Carvalho A,Carneiro V,et al.Clinicopathological significance of ERCC1 expression in breast cancer［J］.Pathology,Research and Practice,2013,209(6):331-336.
［9］Bogush TA,Popova AS,Dudko EA,et al.ERCC1 as a marker of ovarian cancer resistance to platinum drugs［J］.Antibiotiki I Khimioterapiia,2015,60(3-4):42-50.
［10］Bisof V,Zajcpetranovic M,Rakusic Z,et al.The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy:A meta-analysis［J］.Eur Arch Otorhinolaryngol,2015,273(9):2305-2317.
［11］Bai Juan，Zheng Ling，Li Ci，et al.Significance of protein expression level of ERCC1，BRCA1 and RRM1 in chemotherapy plan for the patients with non-small cell lung cancer［J］.Modern Oncology,2016,24(21):3410-3413.［白娟，郑玲，李茨，等.联合检测ERCC1、BRCA1、RRM1表达在非小细胞肺癌选择化疗方案中的意义［J］.现代肿瘤医学，2016,24(21):3410-3413.］
［12］Bai W,Wu Y,Zhang P,et al.Correlations between expression levels of thymidylate synthase,thymidine phosphorylase and dihydropyrimidine dehydrogenase,and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer［J］.Int J Clin Exp Pathol,2015,8(10):12333-12345.
［13］Wakasa K,Kawabata R,Nakao S,et al.Dynamic modulation of thymidylate synthase gene expression and fluorouracil sensitivity in human colorectal cancer cells［J］.PLoS One,2015,10(4):e0123076.
［14］Qiu T,Xiang X,Lei W,et al.Establishment and biological characterization of 5-fluorouracil-resistant human colon cancer HT-29/5-FU cell line［J］.Chin J Cellular Molecular Immunol,2015,31(3):328-332.
［15］Nagaraju GP,Alese OB,Landry J,et al.HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5-FU-based chemotherapy［J］.Oncotarget,2014,5(20):9980-9991.
［16］Ijichi K,Adachi M,Ogawa T,et al.Cell-cycle distribution and thymidilate synthatase (TS) expression correlate with 5-FU resistance in head and neck carcinoma cells［J］.Anticancer research,2014,34(6):2907-2911.
［17］Ligabue A,Marverti G,Liebl U,et al.Transcriptional activation and cell cycle block are the keys for 5-fluorouracil induced up-regulation of human thymidylate synthase expression［J］.PLoS One,2012,7(10):e47318.
［18］Ohashi T,Yoshimasu T,Oura S,et al.Class III beta-tubulin expression in non-small cell lung cancer:A predictive factor for paclitaxel response［J］.Anticancer Research,2015,35(5):2669-2674.
［19］Karki R,Mariani M,Andreoli M,et al.Beta III-tubulin:Biomarker of taxane resistance or drug target［J］.Expert Opinion On Therapeutic Targets,2013,17(4):461-472.
［20］Zheng WE,Chen H,Yuan SF,et al.Overexpression of beta III-tubulin and survivin associated with drug resistance to docetaxel-based chemotherapy in advanced gastric cancer［J］.J BUON,2012,17(2):284-290.

Memo

Memo:
湖南省卫计委基金资助项目（编号：B2011-138）
Last Update: 2017-11-30